BNET Industries

StemCells Inc.

(STEM) is in the Pharma Industry

Market Cap:$159.7M
Last Fiscal Year Sales:$231.7K
  • Public
  • US
Dow Jones Description

StemCells, Inc. is engaged in the discovery and development of cell-based therapeutics to treat damage to, or degeneration of, major organ systems. Our aim is to restore or support organ function, improve patients lives and reduce the substantial health care costs associated with these diseases and disorders by identifying and developing stem and progenitor cells as potential therapeutic agents. We currently have two product development programs at the Company: (i) our CNS Program, which is developing applications for our proprietary human neural stem cell and (ii) our Liver Program, which is developing applications for our proprietary human liver engrafting cells. In our CNS Program, we are focused on developing applications for our HuCNS-SC ® product candidate (purified human neural stem cells) for disorders of the central nervous system (CNS). Our HuCNS-SC product candidate is in clinical development for two indications. In January 2009, we completed a six patient Phase I clinical trial to evaluate the safety and preliminary efficacy of HuCNS-SC cells as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL), two forms of a group of disorders often referred to as Batten disease. We expect to complete data analysis and to report the results of this trial in mid 2009. ...

Number of Employees 55
Contact Information

3155 Porter Dr

Palo Alto, California 94304-1213

stemcellsinc.co...

(650) 475-3100

NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414

Recent Events

  • StemCells STEM Posts Q3 Loss of 5c, Tops by 2c

    11/05/09 - Financial Announcement - View Story

  • StemCells raises $12.5 million through private placement of common stock

    11/04/09 - Licensing / Contract - View Story

  • StemCells STEM Announces First Ever Neural Stem Cell Trial in Myelination Disorder

    9/10/09 - Bond / Stock Rating - View Story

  • STEM CELLS Promotes Miodrag Stojkovic to Editor

    7/01/09 - Mgmt. Change Entering - Other - View Story

News & Analysis

finance and stemcells inc. - All News and Analysis

advertisement
Click Here
     STEM $1.35 +0.05 (3.85% )
Intraday | 3 Month | 6 Month | 1 Year
Average Volume 2,260,060
Shares Outstanding 118.35M
Market Cap 159.8M
Year High 3.07
Year Low 0.89
Earnings Per Share -0.33
P/E Ratio -4.09
Dividend N/A
Yield N/A
IndustryTop Rated

Brought to you by CBS MoneyWatch.com

advertisement
Click Here